CASI Pharmaceuticals, Inc. (CASI) Analysts See $-0.03 EPS

March 15, 2018 - By Marguerite Chambers

 CASI Pharmaceuticals, Inc. (CASI) Analysts See $ 0.03 EPS
Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.53, from 1.67 in 2017Q2. It dived, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported.
Moreover, Renaissance Technology Lc has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 112,900 shares. Raymond James Financial Svcs Advsr stated it has 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Morgan Stanley, a New York-based fund reported 1,157 shares. Wellington Shields Llc holds 725,348 shares. Guggenheim Limited Liability reported 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Geode Capital Llc, a Massachusetts-based fund reported 38,315 shares. 21 are held by Deutsche Bank Ag. 26,053 are owned by Moors Cabot. Blackrock Incorporated has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Virtu Financial Llc has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Everett Harris And Ca reported 0% stake. Vanguard Group Inc Inc Inc reported 358,972 shares. Focused Wealth Mgmt has 45 shares. Wells Fargo Mn stated it has 68 shares. Next Financial Group invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI).

Analysts expect CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report $-0.03 EPS on March, 30.They anticipate $0.02 EPS change or 40.00 % from last quarter’s $-0.05 EPS. After having $-0.03 EPS previously, CASI Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.93% or $0.03 during the last trading session, reaching $3.25. About 50,664 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since March 15, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 5 analyst reports since October 29, 2015 according to SRatingsIntel. The stock of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has “Buy” rating given on Monday, August 14 by Maxim Group. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, October 29. The firm has “Buy” rating by Maxim Group given on Thursday, September 22. The stock has “Buy” rating by H.C. Wainwright on Tuesday, January 16.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $227.19 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The company's late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

More recent CASI Pharmaceuticals, Inc. (NASDAQ:CASI) news were published by: which released: “CASI Pharmaceuticals Inc.” on May 15, 2017. Also published the news titled: “CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference” on February 09, 2018.‘s news article titled: “CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By …” with publication date: October 13, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: